We expected that a successful interpretation of differentially accumulated subsets between EGFR-WT and EGFR-MT would provide clues to understanding the mechanisms underlying unfavorable anti-PD-1 response in patients with EGFR-MT NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.